Current mouse gene targeting technology is unable to introduce somatic mutations at a chosen time and/or in a given tissue. We report here that conditional site-specific recombination can be achieved in mice using a new version of the Cre/lox system. The Cre recombinase has been fused to a mutated ligand-binding domain of the human estrogen receptor (ER) resulting in a tamoxifen-dependent Cre recombinase, Cre-ERT, which is activated by tamoxifen, but not by estradiol. Transgenic mice were generated expressing Cre-ERT under the control of a cytomegalovirus promoter. We show that excision of a chromosomally integrated gene flanked by loxP sites can be induced by administration of tamoxifen to these transgenic mice, whereas no excision could be detected in untreated animals. This conditional sitespecific recombination system should allow the analysis of knockout phenotypes that cannot be addressed by conventional gene targeting.
The study of the genetic control of mammalian development and physiology has been revolutionized by the ability to inactivate (knockout) specific genes by homologous recombination in the mouse (1) . However, using current gene targeting technology, interpretations of knockout phenotypes are often limited by several factors. First, the presence of a selection marker may influence the phenotype of the mutation (2, 3) . Second, artefacts can arise due to the lack of a gene product for the whole lifetime of the animal. Third, the inactivation of a gene may result in intra-utero lethality, precluding analysis of the possible function(s) of the gene at later stages of development and/or post-natally. A conditional gene targeting method based on the inducible activity of an engineered DNA recombinase could overcome these limitations by allowing the removal of the selection cassette and the timed and tissuespecific inactivation of target genes at will during development and in the adult mouse (4) . Furthermore, such an inducible system could help in certain cases to distinguish between anomalies related to a mixed genetic background and those due to mutation of the targeted gene.
The bacteriophage P1 Cre recombinase efficiently excises DNA flanked by two directly repeated loxP recognition sites in mammalian cells (5, 6) . We have previously reported that fusion of the ligand-binding domain (LBD) of the estrogen receptor (ER) to the Cre recombinase generates a chimeric recombinase whose activity in cultured cells is dependent on the presence of an estrogen (estradiol) or an anti-estrogen (tamoxifen) (7) . To achieve conditional gene targeting in mice, where endogenous estradiol is present, we have subsequently fused Cre to a mutated LBD of the human ER (Gly 521 -> Arg, G521R) resulting in the chimeric protein Cre-ERT. Indeed, the corresponding mouse ER LBD mutant (G525R) does not bind 17,B-estradiol (E2), whereas it binds the synthetic ligands tamoxifen and 4-hydroxytamoxifen (OHT) (8) . We report here that Cre-ERT is a functional tamoxifen-dependent recombinase in cultured cells and in transgenic mice.
MATERIALS AND METHODS Construction of Plasmids and Generation of Transgenic
Mice. pCMVCre-ERT was constructed by cloning the 2-kb EcoRI fragment isolated from pCre-ERT into the EcoRI site of the expression vector pMGSV1. pCre-ERT was obtained by first replacing the 252-bp HindIII-BglII fragment of pCre-ER (7) with the corresponding fragment isolated from the expression vector HEGO (9), coding for the human ER containing a glycine at amino acid 400. The amino acid corresponding to glycine 521 of the human ER was then mutated to an arginine by site-directed mutagenesis using the oligonucleotide 5'-CAC-ATGAGTAACAAAAGAATGGAGCATCTGTAC-3'. To obtain pMGSV1, a 600-bp XbaI-HindIII restriction fragment containing the enhancer/promoter region of the major IE gene of the human cytomegalovirus (CMV), isolated from pCMVcat (10) was first cloned into BSM+ (Vector Laboratories cloning systems) digested with XbaI and HindIll, resulting in BSM-CMV. The simian virus 40 promoter region of pSG1 (11) 
RESULTS AND DISCUSSION
To express a tamoxifen-dependent Cre recombinase, we constructed an expression vector, pCre-ERT, encoding the fusion protein Cre-ER T consisting of Gre fused to a mutated LBD of the human ER (GY521R). The functionality of Cre,-ERT was.
tested by transient transfection using a mouse F9 embryonal carcinoma "reporter" cell line, which carries a chromosomally integrated "floxed" tkneo gene, i.e., a tkneo gene that is flanked by two directly repeated loxP sites. In these cells, Cre-ERT excised the tkneo gene in the presence of 1 tLM of OHT, but not in the presence of 100 nM of E2 or in the absence of ligand, whereas, as reported (7), Cre-ER excised the target gene both in the presence of B2 and OHT (Fig. 1) . While the present study was in progress, a similar conditional Cre-ERT recombinase was described (15) .
Transgenic mice expre'ssing Gre-ER T under the control of a CMV promoter were generated (Fig. 2a) [RXRa AF2(LNL), Fig. 2b, B (Fig. 2b) . The relative efficiency 6'f excision was estimated by comparing the intensity of the band amplified from the deleted RXRaAA2(L) allele with that of the band amplified from the wt RXRai allele, which differs in' sequence only by the absence of the loxP site.
Offspring generated by crossing Cre-ERTand RXRa reporter mice, which harbo'red both the Cre-ER Ttransgene and the RXRaAA2(LNL) allele were identified by genotyping of tail biopsies (data not shown). These mice were treated, with OHT at the age of 4 weeks and a'nalyzed for Cre-ERT_mediated DNA excision (Fig. 3a) . Excision of the floxed marker gene was undetectable in oil-treated control animals ( Fig. 3a Upper and data not shown), whereas mice injected intraperitoneally (i.p.) with OHT reproducibly showed excision of the floxed target gene in all organs tested except in the thymus (Fig. 3a Lower and data not shown). Importantly, in the tail the deleted RXRaAAF(L) allele was absent before OHT administration to the animal, whereas its presence was detected following OHT treatment [ Fig. 3a Lower, compare tail(a) with blot analysis (data not shown). These results indicate that Cre-ERT is a tightly regulated recombinase that displays undetectable activity in the absence of its cognate ligand and can be activated in mice by OHT treatment. We did not observe any deleterious effects of OHT treatment during this HPRT study, in agreement with reports indicating that tamoxifen has a very low acute toxicity and causes no severe anomalies in mice (16) . Cre-ERT mRNA was detected in all organs analyzed except in the thymus (Figs. 3b and 4) , suggesting that the protein is expressed in most tissues. Interestingly, the relative level of Cre-ERT mRNA correlated well with the level of DNA excision in the various organs examined (Figs. 3 and 4) . Excision was most efficient in tail, skin, kidney, and spleen where it occurred for 40-50% of the reporter allele. The level of excision was approximately 30% in the liver and stomach and less than 15% in other organs. In the tail, the excision remained at the same level (-50%) after three or five injections of OHT (Fig. 4) . Assuming that in the tail and possibly also in other tissues Cre-ERT expression might be restricted to a subset of specific cells, the actual level of excision in these cells could in fact be higher. Note in this respect that CMVdriven transgene expression is known to vary considerably between different cell types in a given organ (17) .
Cre-ERT_mediated gene excision using the present Cre-ERT expressing transgenic mouse line generates mosaic animals in which cells containing excised and nonexcised target DNA are mixed. Similar mosaics generated with mice homozygous for a targeted gene will allow the analysis of the function of this gene, provided its mutation results in a phenotype that does not depend on the inactivation of the gene in all cells of a given tissue. Furthermore, genetic mosaics can reveal several aspects of the mutant phenotype not necessarily apparent in knockout mutants (18) , and also allow the analysis of mutations that result in lethality during embryogenesis or early post-natal development (19) . Note that creating Cre-ERT mouse lines expressing the conditional recombinase under cell/tissuespecific promoters will allow the selective mutation of a given gene at a given time in a given tissue. Note also that using an efficient inducible promoter system [e.g., one based on tetracycline inducibility (20) ] that expresses the Cre-ERT recombinase may be required to ensure that the recombinase levels are high enough to result in 100% excision of the targeted DNA.
Kuehn et al. (21) recently reported a method for conditional gene targeting in mice based on regulating the expression of a constitutively active Cre recombinase using an interferonresponsive promoter. The interferon-inducible system resulted in some tissues in higher rates of activated excision than those observed with the present Cre-ERT mice, but was not as tightly controlled since background recombination was observed in interferon-untreated animals. We believe that further improvement of ligand-dependent Cre recombinase systems sim- RT-PCR analysis of Cre-ERT mRNA expression. RNA was isolated from the same organs of an untreated littermate transgenic for Cre-ERT, sacrificed on the same day (similar results were obtained when RNA was isolated from OHT-treated animals). PCR products corresponding to the Cre-ERT mRNA and to the HPRT mRNA used as an internal control are indicated. Reactions run without DNA template are also shown. RT-PCR assays performed without RT did not result in any of the products (data not shown). shown. Mice were treated as described in the legend to Fig. 3 . No excision could be detected in untreated animals.
_ --#
